A landmark clinical trial launched in February 2026 is giving TBI patients, families, and attorneys reason to watch carefully. The FIT-BRAIN trial — enrolling patients across eight major U.S. medical centers — is investigating whether fresh frozen plasma traumatic brain injury treatment can stop ongoing brain damage within the critical hours following injury. If proven effective, this would represent the first major breakthrough in TBI care in over 30 years, reshaping not only emergency medicine but also the legal landscape surrounding brain injury claims and settlements. This comes at a critical moment: traumatic brain injury now affects more than 2 million people in the U.S. each year, resulting in nearly 70,000 deaths annually.
What Is the FIT-BRAIN Trial and Why Does It Matter?
The FIT-BRAIN trial is a multi-institutional Phase 2/3 clinical study comparing standard care plus two units of fresh frozen plasma (approximately 400–500ml) against standard care alone in patients who have suffered moderate-to-severe traumatic brain injuries. Launched in February 2026, the trial is being conducted simultaneously across eight premier medical institutions: Vanderbilt University Medical Center, Northwestern Medicine, the University of Southern California, Oregon Health & Science University (OHSU), the Medical College of Wisconsin (MCW), UT Southwestern, UC Davis, and the University of Alabama at Birmingham (UAB).
Vanderbilt researchers are specifically studying whether a single dose of fresh frozen plasma, administered approximately one hour after hospital arrival, can reduce brain lesion growth and lead to measurably better long-term brain function. The coordinated, multi-site structure of the trial is designed to generate statistically robust data across diverse patient populations — a necessity for eventual FDA approval of any new TBI intervention.
The urgency of this research is underscored by the scale of the crisis. The CDC confirmed 68,663 TBI-related deaths in 2023, and the total annual healthcare cost of nonfatal TBIs now exceeds $40.6 billion. For an overview of how traumatic brain injuries are classified and legally recognized, the CDC’s TBI resource center provides foundational definitions and national incidence data that are frequently cited in litigation contexts.
Understanding Secondary Brain Injury: The Silent Damage Window
To understand why fresh frozen plasma traumatic brain injury treatment is generating such excitement, it is essential to understand the two-stage process of TBI damage. Brain damage following trauma occurs in two distinct phases. The first is the immediate, mechanical injury caused by the traumatic event itself — the direct impact that kills or disrupts neurons instantly. The second is secondary brain injury: an ongoing biological cascade of swelling, inflammation, and intracranial bleeding that can persist for hours or even days after the initial trauma, progressively worsening the patient’s condition and long-term outcomes.
This secondary phase is where the most devastating and preventable damage frequently occurs. Current science confirms that TBI causes decreased blood clotting, which leads to continued intracranial bleeding — compounding the initial injury. Alarmingly, as of 2026, there is no approved treatment that directly targets secondary brain injury or limits this ongoing damage. Physicians today are largely limited to supportive care: managing intracranial pressure, maintaining oxygen levels, and preventing complications — but nothing currently available actually stops the progressive neurological destruction occurring at the cellular level.
Fresh frozen plasma is theorized to interrupt this secondary cascade by improving clotting function when administered early, potentially halting the internal bleeding that drives much of the worsening. Animal studies have demonstrated that plasma given within the first few hours of injury protects brain cells and reduces swelling — results compelling enough to justify the rigorous human trials now underway in 2026.
FIT-BRAIN Trial Design: Endpoints, Enrollment, and Timeline
The FIT-BRAIN trial is structured around two primary endpoints: reduction in brain lesion volume as measured by advanced neuroimaging at 30 days post-injury, and improvement in functional neurological outcomes at six months. Secondary endpoints include assessments of coagulation function, intracranial pressure stabilization, and quality-of-life measures extending to one year following injury.
Enrollment targets adults aged 18 and older who present to participating emergency departments within a defined window following moderate-to-severe TBI. The trial uses an exception from informed consent protocol — a standard regulatory mechanism for emergency research — given that the treatment window is too narrow to obtain traditional consent from patients who are frequently unconscious or critically incapacitated at presentation.
Researchers at the eight participating institutions expect to complete enrollment within approximately 24 to 36 months, placing preliminary results potentially within reach by late 2027 or early 2028. If Phase 2/3 data are sufficiently compelling, an accelerated FDA review pathway could bring fresh frozen plasma closer to formal approval as a first-line TBI intervention — a development that would fundamentally alter both clinical protocols and legal standards of care in traumatic brain injury cases.
Legal Implications: How FIT-BRAIN Could Transform TBI Litigation and Settlements
The FIT-BRAIN trial carries enormous implications for attorneys handling traumatic brain injury cases. TBI litigation is already among the most complex and high-value personal injury work. In 2026, TBI settlement amounts typically range from approximately $20,000 for mild cases to over $10 million for catastrophic injuries, with some cases exceeding $26 million depending on the severity of impairment, the degree of negligence, and the long-term care needs of the victim.
If fresh frozen plasma is ultimately validated and approved as the standard of care, it will create an entirely new category of medical negligence claims: cases where a TBI victim was not treated with FFP during the critical early window, resulting in preventable secondary injury and worse long-term outcomes. Attorneys will need to evaluate whether the treating facility had FFP protocols in place, whether the intervention was offered within the appropriate timeframe, and whether the failure to administer FFP constitutes a deviation from the emerging standard of care.
Beyond negligence claims, an approved FFP protocol will affect damages calculations in all TBI cases. Future medical expense projections, life care plans, and lost earning capacity analyses will need to account for whether the injured person received optimal early treatment — and, if not, how that failure affected the trajectory of their recovery. The gap between receiving and not receiving early FFP treatment could represent millions of dollars in differential outcomes and, therefore, differential settlement and verdict values.
The legislative environment is also shifting. In July 2026, the U.S. House unanimously passed bipartisan legislation to reauthorize national traumatic brain injury programs through 2030 — a signal that lawmakers across the political spectrum recognize TBI as a pressing public health and legal priority. This legislative momentum may accelerate both research funding and the pace at which new treatment standards become legally enforceable expectations.
What TBI Victims and Families Should Know Right Now
For TBI victims and their families navigating legal claims in 2026, the FIT-BRAIN trial and the broader evolution of TBI science carry immediate practical significance. First, it is more important than ever to preserve complete and detailed medical records from the earliest moments of emergency treatment. Whether or not FFP was administered, and the specific timeline of all interventions, may become legally significant as trial results emerge and standards of care evolve.
Second, families should understand that the science supporting TBI claims is advancing rapidly. Expert witnesses in TBI litigation are increasingly drawing on neuroimaging data, biomarker evidence, and emerging treatment research to quantify brain injury severity and attribute long-term consequences to specific injury mechanisms. An experienced TBI attorney will work with medical experts who are current on 2026 science — not relying on outdated frameworks that may undervalue a victim’s injuries.
Third, the military population deserves specific mention. From 2000 through the third quarter of 2025, the Defense Health Agency recorded more than 530,000 first-time TBI diagnoses among U.S. Service members — a figure that underscores how broadly this injury affects not only civilian accident victims but also those who have served the country. Veterans and active-duty personnel facing TBI-related legal or benefits claims should seek counsel familiar with both civilian tort law and military-specific compensation systems.
Finally, do not assume that a TBI claim is too complex, too uncertain, or too late to pursue. The legal and medical landscape for brain injury victims in 2026 is more favorable than it has ever been, with growing scientific tools to document injuries that were once invisible and undervalued.
Frequently Asked Questions About Fresh Frozen Plasma and TBI Treatment
What is fresh frozen plasma and how is it used in TBI treatment?
Fresh frozen plasma (FFP) is a blood product derived from donated human plasma that is frozen shortly after collection to preserve its clotting factors and proteins. It has long been used in trauma settings to treat patients with severe bleeding or coagulopathy — conditions where the blood loses its ability to clot properly. In the context of TBI treatment, researchers are investigating whether early administration of FFP can restore clotting function in the brain and surrounding tissue, interrupting the secondary injury cascade that causes progressive neurological damage in the hours after the initial traumatic event.
Why is there no current approved treatment for secondary brain injury?
Secondary brain injury — the ongoing biological damage that follows the initial trauma — has proven extraordinarily difficult to treat despite decades of research. Numerous pharmaceutical interventions that showed promise in animal models have failed to demonstrate benefit in human clinical trials, including progesterone, hypothermia protocols, and various neuroprotective agents. The complexity of the brain’s injury response, combined with the narrow treatment windows involved and the heterogeneity of TBI presentations, has made it exceptionally challenging to design trials that produce clear positive results. As of 2026, supportive care remains the standard, and the FIT-BRAIN trial represents one of the most scientifically credible efforts yet to change that reality.
How could FDA approval of FFP for TBI affect legal settlements?
FDA approval of fresh frozen plasma as a first-line TBI treatment would reshape the legal standard of care for brain injury cases nationwide. Once an intervention is formally approved and incorporated into clinical guidelines, failure to offer it within the appropriate treatment window could constitute medical negligence. This would open new avenues for claims against hospitals and emergency care providers. Additionally, approved treatment protocols affect damages calculations: life care planners and economic experts will need to account for whether optimal early treatment was received and how that affects projected recovery trajectories, long-term care costs, and earning capacity — all of which directly influence settlement values and jury verdicts in TBI cases.
Which hospitals are participating in the FIT-BRAIN trial?
The FIT-BRAIN trial is being conducted at eight major U.S. medical institutions: Vanderbilt University Medical Center, Northwestern Medicine, the University of Southern California, Oregon Health & Science University (OHSU), the Medical College of Wisconsin (MCW), UT Southwestern, UC Davis, and the University of Alabama at Birmingham (UAB). These institutions were selected for their established trauma infrastructure, neurological research capabilities, and patient volume sufficient to support meaningful enrollment within the trial’s timeline.
If a TBI victim wasn’t treated with FFP, does that affect their legal case?
As of 2026, FFP is not yet an approved or mandated standard of care for TBI, so the absence of FFP treatment does not in itself constitute negligence. However, if a victim was treated at one of the FIT-BRAIN participating institutions and was not enrolled or offered enrollment without documented medical justification, that fact may warrant legal scrutiny. More broadly, as the trial progresses and results emerge, the question of whether FFP was available and offered will become increasingly relevant in evaluating the quality of care received. Victims and families should document all treatment decisions carefully and consult with a TBI attorney who is tracking the evolving science and its legal implications throughout 2026 and beyond.
Robert Callahan is a TBI and Catastrophic Injury Researcher with extensive knowledge of personal injury law and settlement values across the United States. With years of experience analyzing brain injury / tbi claims only cases, Robert helps injury victims understand their legal rights and the potential value of their claims. Robert is not an attorney and the information provided is for educational purposes only.